590 related articles for article (PubMed ID: 18986388)
1. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
2. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
3. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
Kaiser M; Zavrski I; Sterz J; Jakob C; Fleissner C; Kloetzel PM; Sezer O; Heider U
Haematologica; 2006 Feb; 91(2):248-51. PubMed ID: 16461312
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
Fortunati N; Bertino S; Costantino L; Bosco O; Vercellinatto I; Catalano MG; Boccuzzi G
Cancer Lett; 2008 Feb; 259(2):156-64. PubMed ID: 18006146
[TBL] [Abstract][Full Text] [Related]
7. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
Wu Y; Guo SW
Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
[TBL] [Abstract][Full Text] [Related]
9. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Gao D; Xia Q; Lv J; Zhang H
Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
[TBL] [Abstract][Full Text] [Related]
11. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
15. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Takai N; Kawamata N; Gui D; Said JW; Miyakawa I; Koeffler HP
Cancer; 2004 Dec; 101(12):2760-70. PubMed ID: 15536623
[TBL] [Abstract][Full Text] [Related]
16. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors.
Cho HH; Park HT; Kim YJ; Bae YC; Suh KT; Jung JS
J Cell Biochem; 2005 Oct; 96(3):533-42. PubMed ID: 16088945
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.
Aouali N; Palissot V; El-Khoury V; Moussay E; Janji B; Pierson S; Brons NH; Kellner L; Bosseler M; Van Moer K; Berchem G
Br J Haematol; 2009 Dec; 147(5):662-71. PubMed ID: 19793255
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways.
Chen Q; Ouyang DY; Geng M; Xu LH; Zhang YT; Wang FP; He XH
J Immunotoxicol; 2011; 8(3):210-8. PubMed ID: 21457087
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo.
Sami S; Höti N; Xu HM; Shen Z; Huang X
J Biochem; 2008 Sep; 144(3):357-62. PubMed ID: 18515856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
